{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:21:27Z","timestamp":1764588087051,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.transci.2020.102850","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T21:38:26Z","timestamp":1591738706000},"page":"102850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-SARS-CoV-2 hyperimmune plasma workflow"],"prefix":"10.1016","volume":"59","author":[{"given":"Petrungaro","family":"Annamaria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quartarone","family":"Eugenia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sciarrone","family":"Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2020.102850_bib0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2020.102850_bib0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3748\/wjg.v9.i6.1139","article-title":"Advances in clinical diagnosis and treatment of severe acute respiratory syndrome","volume":"9","author":"Nie","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.transci.2020.102850_bib0015","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.transci.2020.102850_bib0020","doi-asserted-by":"crossref","first-page":"P398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.transci.2020.102850_bib0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Yoy","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.transci.2020.102850_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.transci.2020.102850_bib0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1471-4906(03)00228-X","article-title":"Antibody-mediated regulation of cellular immunity and the inflammatory response","volume":"24","author":"Casadevall","year":"2003","journal-title":"Trends Immunol"},{"key":"10.1016\/j.transci.2020.102850_bib0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2020.102850_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulinin neurology--mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"June(6)","key":"10.1016\/j.transci.2020.102850_bib0050","article-title":"The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.transci.2020.102850_bib0055","article-title":"Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)","author":"Wan","year":"2020","journal-title":"MedRxiv"},{"issue":"17","key":"10.1016\/j.transci.2020.102850_bib0060","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.transci.2020.102850_bib0065","doi-asserted-by":"crossref","DOI":"10.1111\/vox.12926","article-title":"Collecting and evaluating convalescent plasma forCOVID-19 treatment: why and how","author":"Tiberghien","year":"2020","journal-title":"Vox Sang"},{"issue":"7-8","key":"10.1016\/j.transci.2020.102850_bib0070","first-page":"42","article-title":"Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV","volume":"56","author":"Shchukina","year":"2011","journal-title":"Antibiot Khimioter"},{"issue":"November (4)","key":"10.1016\/j.transci.2020.102850_bib0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy forpatients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"19","author":"Arabi","year":"2015","journal-title":"Springer plus"},{"key":"10.1016\/j.transci.2020.102850_bib0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.transci.2020.102850_bib0085","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2783","article-title":"Positive RT-PCR test results in patients recovered from COVID-19","author":"Lan","year":"2020","journal-title":"JAMA"},{"year":"2015","series-title":"Disposizioni relative ai requisiti di qualita\u2019 e sicurezza del sangue e degli emocomponenti","author":"GazzettaUfficiale","key":"10.1016\/j.transci.2020.102850_bib0090"},{"year":"2017","series-title":"Guide to the preparation, use and quality assurance of blood components","author":"European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe","key":"10.1016\/j.transci.2020.102850_bib0095"},{"key":"10.1016\/j.transci.2020.102850_bib0100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"Wang","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.transci.2020.102850_bib0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.transci.2020.102850_bib0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human Primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.transci.2020.102850_bib0115","article-title":"Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster","author":"Woelfel","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.transci.2020.102850_bib0120","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc070348","article-title":"Disappearance of antibodies to SARS-associated coronavirus after recovery","volume":"357","author":"Cao","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2020.102850_bib0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/653940","article-title":"Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009","volume":"51","author":"Hung","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2020.102850_bib0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.diagmicrobio.2017.07.006","article-title":"Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity","volume":"89","author":"Ko","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.transci.2020.102850_bib0135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/653940","article-title":"Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009","volume":"51","author":"Hung","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2020.102850_bib0140","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.diagmicrobio.2017.07.006","article-title":"Serologic responses of 42 MERS-coronavirus- infected patients according to the disease severity","volume":"89","author":"Ko","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.transci.2020.102850_bib0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jmv.20431","article-title":"A serological survey on neutralizing antibody titer of SARS convalescent sera","volume":"77","author":"Zhang","year":"2005","journal-title":"J Med Virol"},{"year":"2020","series-title":"China puts 245 COVID-19 patients on convalescent plasma therapy Xinhua","author":"Xinhua","key":"10.1016\/j.transci.2020.102850_bib0150"},{"key":"10.1016\/j.transci.2020.102850_bib0155","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.transci.2020.102850_bib0160","article-title":"The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study","author":"Duan","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.transci.2020.102850_bib0165","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","author":"Bloch","year":"2020","journal-title":"J Clin Invest"},{"year":"2020","series-title":"US food & drug administration development & approval process (CBER) investigational COVID-19 convalescent plasma - emergency INDs","key":"10.1016\/j.transci.2020.102850_bib0170"},{"year":"2014","series-title":"Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks","author":"WHO","key":"10.1016\/j.transci.2020.102850_bib0175"},{"key":"10.1016\/j.transci.2020.102850_bib0180","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1128\/JVI.00671-11","article-title":"Anti-severeacute respiratory syndrome coronavirus spike antibodies trigger infection of humanimmune cells via a pH- and cysteine protease-independent Fc gamma R pathway","volume":"85","author":"Jaume","year":"2011","journal-title":"JVirol"},{"key":"10.1016\/j.transci.2020.102850_bib0185","first-page":"291","article-title":"Influence of Fc gamma RIIA and MBL polymorphisms on severe acute respiratory syndrome","volume":"66","author":"Yuan","year":"2005","journal-title":"TissueAntigens"},{"issue":"June","key":"10.1016\/j.transci.2020.102850_bib0190","article-title":"Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of anti body dependent Enhancement","volume":"127","author":"Fleming","year":"2020","journal-title":"J Clin Virol"},{"year":"2020","series-title":"SIMTI \/SIDEM \u201cPosition paper\u201d sulla produzione di plasma iperimmune da utilizzare nella terapia della malattia da SARS-CoV2","key":"10.1016\/j.transci.2020.102850_bib0195"},{"issue":"March (3)","key":"10.1016\/j.transci.2020.102850_bib0200","first-page":"316","article-title":"Effect of heat inactivation of blood samples on the efficacy of three detection methods of SARS-CoV-2 antibodies","volume":"40","author":"Xue","year":"2020","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"year":"2020","series-title":"Clinicaltrials.gOv hyperimmune plasma for critical patients with COVID-19 (COV19 PLASMA)","key":"10.1016\/j.transci.2020.102850_bib0205"},{"issue":"5","key":"10.1016\/j.transci.2020.102850_bib0210","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections:\u2019 super-antibodies\u2019 enter the fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.transci.2020.102850_bib0215","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220301531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220301531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:52:20Z","timestamp":1761468740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050220301531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1473050220301531"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2020.102850","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-SARS-CoV-2 hyperimmune plasma workflow","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2020.102850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102850"}}